Single oral dose of VARUBI® prior to chemotherapy as part of an antiemetic regimen1
Other drug interactions
- Strong CYP3A4 inducers: Avoid use of VARUBI in patients who require chronic administration of strong CYP3A4 inducers (e.g., rifampin) as significantly reduced plasma concentrations of VARUBI can decrease the efficacy of VARUBI
- BCRP and P‐gp substrates with a narrow therapeutic index: Oral VARUBI is an inhibitor of breast cancer resistance protein (BCRP) and P‐glycoprotein (P-gp). Increased plasma concentrations of BCRP substrates (e.g., methotrexate, topotecan, or irinotecan) and P-gp substrates (e.g., digoxin) with a narrow therapeutic index may result in potential adverse reactions. Monitor for adverse reactions related to the concomitant drug if use with VARUBI cannot be avoided. Monitor digoxin concentrations with concomitant use of VARUBI, and adjust the dosage as needed to maintain therapeutic concentrations
- Warfarin: Monitor INR and prothrombin time and adjust the dosage of warfarin, as needed, to maintain target INR
Single-dose wallet card contains two 90-mg tablets1
- 1 dose, no dose adjustments of dexamethasone, and choice of 5-HT3 RA1
- Tablets can be taken with or without food
- VARUBI is effective when taken 2 hours (at the earliest) to 1 minute (at the latest) prior to chemotherapy treatment1
- VARUBI is the only NK-1RA with a long half-life of ≈7 days, lasting through the delayed CINV phase following chemotherapy.1 Patients do not need to take a follow-up dose of VARUBI before 14 days after the previous dose
See full dosing regimen below.
VARUBI dosing regimen1
Combined antiemetic regimen dosing with VARUBI, a 5-HT3 RA, and dexamethasone for the prevention of nausea and vomiting in the delayed phase associated with HEC and MEC1
5-HT3, 5-hydroxytryptamine-3 (serotonin); HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; RA, receptor antagonist.
Reference: 1. VARUBI® Prescribing Information, TerSera Therapeutics LLC